Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more
Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
46.01M
52 Wk Range
$2.28 - $24.15
Previous Close
$2.46
Open
$2.43
Volume
203,565
Day Range
$2.35 - $2.52
Enterprise Value
-51.03M
Cash
101M
Avg Qtr Burn
-5.898M
Insider Ownership
17.19%
Institutional Own.
70.34%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|